Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone
November 17 2020 - 8:32AM
Business Wire
University of Pennsylvania scientists recognized for their
contributions to the field of CAR T-cell mediated cancer
immunotherapy
Agilent Technologies Inc. (NYSE: A) today announced professors
Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of
an Agilent Thought Leader Award. Both scientists are being
recognized for their joint contributions to the field of CAR T-cell
mediated cancer immunotherapy, having codeveloped tisagenlecleucel
(Kymriah™), the first cell and gene therapy product approved by the
US FDA.
The award will focus on defining standards for the design,
validation, and manufacturing of cell-based cancer therapeutics.
Combining metabolomic and cell-based tools with more efficient
CRISPR-based engineering of T-cells will allow labs to validate and
maintain quality control downstream in development and
manufacturing.
Agilent will provide modified gRNAs and oligonucleotide
libraries to optimize the engineering of patient T-cells. Agilent
will also provide instruments including an xCELLigence RTCA eSight,
a NovoCyte Quanteon Flow Cytometer, a 6546 LC/Q-TOF Mass
Spectrometer, and a 2100 Bioanalyzer system, which will work in
concert with cell engineering advances to enable the development of
protocols and workflows for characterization and selection of the
best approaches to T-cell engineering.
“It’s an honor to be chosen for an Agilent Thought Leader Award.
Partnering with Agilent will help strengthen our research in areas
with a critical impact on cancer treatment,” said Dr. June.
“Receiving this Agilent award will enable us to improve the
generation and characterization of cell-based products and
therapeutics,” added Dr. Milone.
“The Thought Leader Award program is about promoting fundamental
scientific advancements,” said Kevin Meldrum, vice president and
general manager of Agilent’s Genomics Division, and executive
sponsor of the award. “The work of Drs. June and Milone embody what
Agilent aims to celebrate and advance.”
Dr. June is the Richard W. Vague Professor of Immunotherapy,
director of the Center for Cellular Immunotherapies, and director
of the Parker Institute for Cancer Immunotherapy at the Perelman
School of Medicine of the University of Pennsylvania. He is a
graduate of the Naval Academy in Annapolis and Baylor College of
Medicine in Houston, 1979. Dr. Milone is an associate professor of
Pathology and Laboratory Medicine and founding member of the Center
for Cellular Immunotherapies at the Perelman School of Medicine. He
is a graduate of Stevens Institute of Technology and earned his MD
and Ph.D. in 1999 from the University of Medicine and Dentistry of
New Jersey.
The Agilent Thought Leader Award program promotes fundamental
scientific advances by contributing financial support, products,
and expertise to the research of influential thought leaders in the
life sciences, diagnostics, and chemical analysis space. To learn
more, visit the Agilent Thought Leader Award webpage.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. In its 20th
year as an independent company delivering insight and innovation
toward improving the quality of life, Agilent instruments,
software, services, solutions, and people provide trusted answers
to customers' most challenging questions. The company generated
revenue of $5.16 billion in fiscal 2019 and employs 16,300 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201117005814/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024